loncastuximab tesirine 在弥漫大 B 细胞淋巴瘤 CAR-T 细胞治疗后效果如何？一项真实世界证据研究的通俗语言总结

What is this summary about? This article provides a plain language summary of a real-world study that evaluated patients with diffuse large B-cell lymphoma who received loncastuximab tesirine , or Lonca, when their disease got worse after chimeric antigen receptor T-cell treatment, commonly referred to as CAR-T treatment . Researchers evaluated the chart data of 118 adults who started Lonca after their lymphoma did not respond to or came back after receiving CAR-T. Researchers examined how patients did in 2 groups: patients who received CAR-T and Lonca earlier in their patient journey (patients who received second-line CAR-T treatment then third-line Lonca) and patients who received CAR-T and Lonca later in their patient journey (patients who received third-line CAR-T treatment then fourth-line Lonca). What were the results?

Of the 95 patients who received second-line CAR-T and third-line Lonca, 73% had their lymphoma respond to Lonca. At 12 months, 84% of patients were still alive, 77% of patients were still alive without their lymphoma getting worse, and 68% of patients had lymphoma that continued to respond to Lonca without getting worse. Of the 23 patients who received third-line CAR-T and fourth-line Lonca, 78% had their lymphoma respond to Lonca.

At 12 months, 95% of patients were still alive, 27% of patients were still alive without their lymphomas getting worse, and 22% of patients had lymphoma that continued to respond to Lonca without getting worse. What do the results mean? Researchers found that Lonca is an effective treatment to use in patients with diffuse large B-cell lymphoma that did not respond to or came back after receiving CAR-T. [Box: see text].